Cargando…

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients

Introduction: Clinical outcomes for patients with hematologic malignancy and COVID-19 have not been aggregated. We completed a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. Methods: We searched Pubmed and EMBASE up to July 25, 2020...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vijenthira, Abi, Gong, Inna, Fox, Thomas A, Booth, Stephen, Cook, Gordon, Fattizzo, Bruno, Martín Moro, Fernando, Razanamahery, Jerome, Riches, John, Zwicker, Jeffrey I., Patell, Rushad, Vekemans, Marie Christiane, Scarfo, Lydia, Chatzikonstantinou, Thomas, Yildiz, Halil, Lattenist, Raphael, Mantzaris, Ioannis, Wood, William, Hicks, Lisa K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	902.Health Services Research-Malignant Conditions (Lymphoid Disease)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330320/ http://dx.doi.org/10.1182/blood-2020-141235

Ejemplares similares

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience
por: Suleman, Adam, et al.
Publicado: (2021)

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis
por: Gong, Inna, et al.
Publicado: (2021)

Worldwide Examination of Patients with CLL Hospitalized for COVID-19
por: Roeker, Lindsey E, et al.
Publicado: (2020)

FREQUÊNCI33DE COVID-19 ENTRE PORTADORES DE NEOPLASIAS HEMATOLÓGICAS: RESULTADOS DE PROGRAMA DE TRIAGEM AMPLA NO DECORRER DA PANDEMIA
por: Garnica, M., et al.
Publicado: (2020)

A Large London District General Hospital Highlights CLL and Bame As Risk Factors for Severe Disease Amongst Haematology-Oncology Patients
por: Farmer, Isabel, et al.
Publicado: (2020)

Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic
por: Mussetti, Alberto, et al.
Publicado: (2020)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)
por: Battiwalla, Minoo, et al.
Publicado: (2020)

Management of Indian Haematology Patients during COVID19 Crisis
por: Subash, Chezhian, et al.
Publicado: (2020)

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic
por: Cashman, Helen, et al.
Publicado: (2020)

Treating Acute Leukemia during the COVID-19 Pandemic: A Multicenter Latin American Registry
por: Demichelis, Roberta, et al.
Publicado: (2020)

Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection
por: Lopez, Carlos A, et al.
Publicado: (2020)

Mobile-Health Tool to Improve Care of Patients with Hematological Malignancies
por: Sanyal, Amit, et al.
Publicado: (2020)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

COVID-19 Incidence in Asymptomatic Cancer Patients Undergoing Chemotherapy
por: Monteiro, Claudia, et al.
Publicado: (2021)

Online Patient-Reported Platform Detects Trend of Increased COVID-19 Risk and Severity for Multiple Myeloma Patients on Active Lenalidomide-Based Therapy
por: Liu, Emily I., et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies
por: Ling, Ying, et al.
Publicado: (2021)

A Prospective Survey to Understand the Preferences and Perspectives of Patients with Hematological Malignancies in a Tertiary Cancer Care Setting in India (CANCOV SURVEY)
por: Sharma, Dr. Neha, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States
por: Goyal, Gaurav, et al.
Publicado: (2021)

Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
por: Weissinger, Stephanie E., et al.
Publicado: (2022)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

Immune reconstitution in children following chemotherapy for acute leukemia
por: Williams, Anthony P., et al.
Publicado: (2020)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

The contribution of human papilloma virus infection to cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia
por: Bhavsar‐Bhakta, Preeya, et al.
Publicado: (2021)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
por: Kostakoglu, Lale, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Marginal zone lymphoma expression of histidine‐rich glycoprotein correlates with improved survival
por: Persson Skare, Tor, et al.
Publicado: (2020)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2d2hbtupugp04v69jg2vtfod0f